NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Epigenomics AG (XETRA: ECX)
ECX Technical Analysis
2
As on 23rd Feb 2023 ECX STOCK Price closed @ 0.76 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.64 & Strong Sell for SHORT-TERM with Stoploss of 1.04 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ECXSTOCK Price
Open | 0.76 | Change | Price | % |
High | 0.76 | 1 Day | -0.02 | -2.56 |
Low | 0.76 | 1 Week | -0.65 | -46.10 |
Close | 0.76 | 1 Month | -0.84 | -52.50 |
Volume | N/A | 1 Year | -0.41 | -35.04 |
52 Week High 1.70 | 52 Week Low 0.30 |
XETRA Germany Most Active Stocks
LHAR | 2.05 | -20.23% |
BBVA | 5.00 | -2.72% |
BBVA | 5.00 | -2.72% |
BBVA | 5.00 | -2.72% |
BVBA | 0.02 | -60.00% |
SNH | 0.16 | 6.67% |
SNH | 0.16 | 6.67% |
SNH | 0.16 | 6.67% |
AT1 | 1.15 | 5.50% |
AT1 | 1.15 | 5.50% |
XETRA Germany Top Gainers Stocks
XETRA Germany Top Losers Stocks
ECX Daily Charts |
ECX Intraday Charts |
Whats New @ Bazaartrend |
ECX Free Analysis |
|
ECX Important Levels Intraday
RESISTANCE | 0.76 |
RESISTANCE | 0.76 |
RESISTANCE | 0.76 |
RESISTANCE | 0.76 |
RESISTANCE | 0.76 |
RESISTANCE | 0.76 |
RESISTANCE | 0.76 |
RESISTANCE | 0.76 |
ECX Forecast May 2024
4th UP Forecast | 1.53 |
3rd UP Forecast | 1.28 |
2nd UP Forecast | 1.13 |
1st UP Forecast | 0.98 |
1st DOWN Forecast | 0.54 |
2nd DOWN Forecast | 0.39 |
3rd DOWN Forecast | 0.24 |
4th DOWN Forecast | -0.01 |
ECX Weekly Forecast
4th UP Forecast | 1.15 |
3rd UP Forecast | 1.02 |
2nd UP Forecast | 0.95 |
1st UP Forecast | 0.87 |
1st DOWN Forecast | 0.65 |
2nd DOWN Forecast | 0.57 |
3rd DOWN Forecast | 0.50 |
4th DOWN Forecast | 0.37 |
ECX Forecast2024
4th UP Forecast | 3.55 |
3rd UP Forecast | 2.66 |
2nd UP Forecast | 2.1 |
1st UP Forecast | 1.55 |
1st DOWN Forecast | -0.03 |
2nd DOWN Forecast | -0.58 |
3rd DOWN Forecast | -1.14 |
4th DOWN Forecast | -2.03 |
Epigenomics AG ( XETRA Germany Symbol : ECX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ECX Other Details
Segment | EQ | |
Market Capital | 12177896.00 | |
Sector | Healthcare | |
Industry | Diagnostics & Research | |
Offical website | > echo $website ; ?> |
ECX Address
ECX Latest News
ECX Business Profile
Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Address: Geneststrasse 5, Berlin, Germany, 10829
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service